LLY

1,021.56

+3.16%↑

JNJ

229.5

+1.7%↑

ABBV

207.35

-0.79%↓

UNH

402.23

+2.43%↑

AZN

186.64

+0.98%↑

LLY

1,021.56

+3.16%↑

JNJ

229.5

+1.7%↑

ABBV

207.35

-0.79%↓

UNH

402.23

+2.43%↑

AZN

186.64

+0.98%↑

LLY

1,021.56

+3.16%↑

JNJ

229.5

+1.7%↑

ABBV

207.35

-0.79%↓

UNH

402.23

+2.43%↑

AZN

186.64

+0.98%↑

LLY

1,021.56

+3.16%↑

JNJ

229.5

+1.7%↑

ABBV

207.35

-0.79%↓

UNH

402.23

+2.43%↑

AZN

186.64

+0.98%↑

LLY

1,021.56

+3.16%↑

JNJ

229.5

+1.7%↑

ABBV

207.35

-0.79%↓

UNH

402.23

+2.43%↑

AZN

186.64

+0.98%↑

Home・Akciju saraksts・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Atvērts

29.01 -0.21

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

28.42

Max

29.38

Galvenie mērījumi
By Trading Economics
Ienākumi	-30M -30M
Pārdošana	-26M 77M
Peļņas marža	-38.823
Darbinieki	524
EBITDA	-12M -8M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+112.73% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-214M 1.4B
Iepriekšējā atvēršanas cena	29.22
Iepriekšējā slēgšanas cena	29.01

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

27.895 / 30.16 Atbalsts un pretestība

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. maijs 22:50 UTC

Peļņas

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

2026. g. 12. maijs 22:49 UTC

Peļņas

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

2026. g. 12. maijs 22:32 UTC

Peļņas

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

2026. g. 12. maijs 23:48 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

2026. g. 12. maijs 22:57 UTC

Tirgus saruna

Peļņas

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

2026. g. 12. maijs 22:26 UTC

Peļņas

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

2026. g. 12. maijs 22:25 UTC

Peļņas

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

2026. g. 12. maijs 22:25 UTC

Peļņas

Aristocrat Leisure Interim Dividend A$0.50/Security

2026. g. 12. maijs 22:24 UTC

Peļņas

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

2026. g. 12. maijs 22:23 UTC

Peļņas

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

2026. g. 12. maijs 22:23 UTC

Peļņas

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

2026. g. 12. maijs 22:19 UTC

Peļņas

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

2026. g. 12. maijs 22:14 UTC

Peļņas

CBA: Business Lending Continued to Grow Above System>CBA.AU

2026. g. 12. maijs 22:14 UTC

Peļņas

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

2026. g. 12. maijs 22:13 UTC

Peļņas

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

2026. g. 12. maijs 22:12 UTC

Peļņas

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

2026. g. 12. maijs 22:12 UTC

Peļņas

CBA 3Q New Home Loan Funding A$45B>CBA.AU

2026. g. 12. maijs 22:11 UTC

Peļņas

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

2026. g. 12. maijs 22:11 UTC

Peļņas

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

2026. g. 12. maijs 22:10 UTC

Peļņas

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

2026. g. 12. maijs 22:09 UTC

Peļņas

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

2026. g. 12. maijs 22:09 UTC

Peļņas

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

2026. g. 12. maijs 22:08 UTC

Peļņas

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

2026. g. 12. maijs 22:07 UTC

Peļņas

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

2026. g. 12. maijs 22:06 UTC

Peļņas

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

2026. g. 12. maijs 22:06 UTC

Peļņas

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

2026. g. 12. maijs 22:05 UTC

Peļņas

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

2026. g. 12. maijs 22:04 UTC

Peļņas

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

2026. g. 12. maijs 22:04 UTC

Peļņas

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

2026. g. 12. maijs 22:04 UTC

Peļņas

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

112.73% augšup

Prognoze 12 mēnešiem

Vidējais 62.33 USD 112.73%

Augstākais 100 USD

Zemākais 33 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

27.895 / 30.16Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.